Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06960993 · ClinicalTrials.gov registry record · NA

Mosaic Trial for Stem Cell Transplant Recipients

A NA study of Multiple Myeloma and Lymphoma, sponsored by Northwestern University.

Recruiting
Registry status
NA
Development phase
356
Enrollment target
3
Study locations

NCT06960993 is a NA study of Multiple Myeloma and Lymphoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 356 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (35% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06960993, a NA study of Multiple Myeloma and Lymphoma, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
NA
Development phase
356 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.

Interventions

  • BEHAVIORAL Intervention website
  • BEHAVIORAL Enhanced Usual Care (Control) Website

Study Locations (3)

District of Columbia

  • Georgetown University School of Medicine - Washington D.C.

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago

New Jersey

  • Hackensack Meridian Health - Nutley

Trial Details

FieldValue
Enrollment Target 356 participants
Start Date 2025-04-28
Est. Completion 2030-02-01
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT06960993

The ClinicalTrials.gov registry entry for NCT06960993 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (35% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Intervention website is the first listed.

NCT06960993 reports 3 study locations spanning 3 distinct geographic areas - top geographies include District of Columbia, Illinois, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06960993 about?

NCT06960993 is a clinical study titled "Mosaic Trial for Stem Cell Transplant Recipients". The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recrui...

What is the current status of trial NCT06960993?

This trial is currently recruiting. It is a NA study. The enrollment target is 356 participants. The study started on 2025-04-28. Estimated completion is 2030-02-01.

What conditions does trial NCT06960993 study?

This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Leukemia, Myelodysplastic Syndromes, Hematologic Malignancy.

What interventions are being tested in trial NCT06960993?

The interventions under investigation include: Intervention website (BEHAVIORAL), Enhanced Usual Care (Control) Website (BEHAVIORAL).

Who is sponsoring clinical trial NCT06960993?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06960993 being conducted?

This trial has 3 study locations across District of Columbia, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.